Persons with hepatitis C virus (HCV) infection are at risk of progressive liver disease, cirrhosis, and decompensation. We analyzed the effects of the direct-acting antiviral agents elbasvir and grazoprevir in patients with HCV infection and compensated cirrhosis, combining data from 6 clinical trials. METHODS: We performed an integrated analysis of 402 patients with HCV genotype 1, 4, or 6 infection and Child-Pugh A compensated cirrhosis enrolled in 6 clinical trials. All patients received elbasvir/grazoprevir 50 mg/100 mg once daily, with or without ribavirin, for 12À18 weeks. The primary end point was sustained virologic response 12 weeks after completion of therapy (SVR12), defined as a level of HCV RNA <15 IU/mL. RESULTS: Among treatment-naïve and treatmentexperienced patients receiving elbasvir/grazoprevir for 12 weeks, 97.8% (135 of 138) and 88.9% (48 of 54) achieved SVR12, respectively. Among patients receiving elbasvir/ grazoprevir for 12 weeks, addition of ribavirin did not increase the proportion of treatment-naïve patients (90.3%, 28 of 31) or treatment-experienced patients who achieved an SVR12 (91.4%, 74 of 81). All (49 of 49) treatment-experienced patients receiving elbasvir/grazoprevir with ribavirin for 16 or 18 weeks, and 93.9% (46 of 49) of patients receiving elbasvir/ grazoprevir without ribavirin for 16 or 18 weeks achieved SVR12. Virologic failure was higher among patients with HCV genotype 1a infections compared with patients with genotype 1b or 4 infections, particularly in patients who had not responded to previous interferon therapy. Baseline tests for resistance-associated substitutions (RASs) led to an individualized approach for selecting treatment duration and established a need for ribavirin for patients with HCV genotype 1a infection and RASs, regardless of treatment history. Among patients with HCV genotype 1a infection with and without baseline RASs in HCV nonstructural protein 5A who received elbasvir/grazoprevir for 12 weeks, 73% (8 of 11) and 98% (96 of 98) achieved SVR12, respectively. Both patients with HCV genotype 1a infection with baseline RASs who received 16 or 18 weeks of elbasvir/grazoprevir and ribavirin achieved SVR12. Grade 3 or 4 increases in levels of alanine aminotransferase and aspartate aminotransferase, which did not cause symptoms, were reported in 2.3% (6 of 264) of patients receiving elbasvir/grazoprevir. Serious adverse events were reported in 3% (8 of 264) patients and no patient had a decompensation-related event. CONCLUSIONS: In an analysis of data from 6 clinical trials, rates of SVR12 ranged from 89% to 100% in patients with HCV genotype 1, 4, or 6 infections and compensated cirrhosis treated with elbasvir/grazoprevir, with or without ribavirin. Addition of ribavirin to a 12-week regimen of elbasvir/grazoprevir had little effect on the proportion of treatment-naïve or treatment-experienced patients who achieved an SVR12. However, virologic failure did not occur in any treatment-experienced patients when the duration of elbasvir/ grazoprevir and ribavirin therapy was extended to 16 or 18 weeks. Baseline analysis of RASs (or in the absence of this test, a history of nonresponse to interferon) can be used to determine treatment duration and the need for ribavirin in patients with HCV genotype 1a infection. Clinicaltrials
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Keywords: NS5A; Virus Mutation; Fibrosis; ALT. P eople infected with the hepatitis C virus (HCV) are at risk of progressive liver disease, which ultimately leads to cirrhosis and sequelae such as decompensation and hepatocellular carcinoma. The estimated prevalence of cirrhosis 20 years after initial infection is 16%. 1 In patients with cirrhosis (METAVIR F4 on biopsy), the estimated risk of progression to hepatic decompensation events or hepatocellular carcinoma is 37.2% at 5 years. 2 Estimates suggest that a period of 40 years will elapse between the peak incidence of HCV infection (in the 1980s) and the peak prevalence of HCV-related cirrhosis, implying that HCV-related cirrhosis will peak during the 2020s at an estimated 1.04 million cases.
Recent studies have shown that treating HCV reduces all-cause mortality, even in patients with cirrhosis 4, 5 ; however, patients with HCV infection and cirrhosis have long been regarded as difficult to treat, typified by low response rates and poor tolerability to interferon-based regimens. 6, 7 Although treatments have improved, with all-oral regimens now the accepted standard of care, many patients with cirrhosis still require intensified treatment regimens. 8, 9 Currently approved all-oral direct-acting antiviral regimens for treatment-naïve and treatment-experienced compensated cirrhotic patients with HCV genotype (GT)1 infection include 12-week regimens of sofosbuvir/ledipasvir, sofosbuvir/velpatasvir, and elbasvir/grazoprevir (EBR/ GZR; in the United States for all GT1b patients and GT1a patients without baseline NS5A resistance variants, with 16 weeks of EBR/GZRþribavirin [RBV] for GT1a-infected patients with baseline resistance-associated substitutions [RASs] ). Cirrhotic patients who are not suitable for these regimens, such as those who have failed a prior treatment regimen that included a direct-acting antiviral agent, might need alternative regimens that require treatment durations of 24 weeks or addition of RBV to attain high rates of sustained virologic response at 12 weeks (SVR12). 8, 9 The combination of EBR, an HCV NS5A inhibitor, and GZR, an NS3/4A protease inhibitor, has been shown to be a safe and highly effective treatment for chronic HCV infection in phase 2/3 clinical trials.
10À15 EBR/GZR is administered once daily, without regard to food intake, and in vitro has been shown to retain activity against many clinically relevant RASs.
16À18 Phase 3 studies of EBR/GZR in patients with HCV GT1, 4, or 6 infection have evaluated a diverse population of patients, including treatment-naïve 11 and treatment-experienced 13, 19 patients, and those with human immunodeficiency virus (HIV) co-infection 10 or stage 4/5 chronic kidney disease. 12 In these populations, EBR/GZR has a generally favorable tolerability profile, with very few serious adverse events (AEs) or discontinuations due to AEs seen in phase 2/3 studies to date. 20 Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevations reported with high-dose GZR (400À800 mg/d) in a phase 2 study 21 are uncommon in patients who receive lower doses of GZR (100 mg/d), occurring in <1% of patients and generally resolving with continued therapy or scheduled end of therapy. 20 Patients with compensated, Child-Pugh A cirrhosis were allowed entry into the EBR/GZR phase 2/3 clinical trial program, and we have therefore conducted an integrated analysis of 402 patients with HCV GT1, 4, or 6 infection and compensated cirrhosis who received EBR/GZR alone or with RBV in these studies.
Methods
This is an integrated analysis of data from 6 international phase 2/3 clinical trials. All studies were carried out in accordance with the Declaration of Helsinki, current guidelines on Good Clinical Practices, and local ethical and legal requirements. All patients provided voluntary written informed consent before trial entry. The detailed methodology and primary outcomes from these studies have been published previously (Phase 3: C-SURFER 12 
Patients
Patients enrolled in these studies were aged older than 18 years and had chronic HCV GT 1, 4, or 6 infection and HCV RNA at baseline >10,000 IU/mL. They were either treatment-naïve or had previously failed HCV therapy with peginterferon/RBV (PR) with or without a first-generation protease inhibitor (boceprevir, telaprevir, or simeprevir). 13 Treatmentexperienced patients had prior response categorized as prior relapse (undetectable HCV RNA at end of treatment followed by detectable HCV RNA during follow-up) or prior on-treatment failure (prior partial or null response, protocol-defined as >2 log decline in HCV RNA but quantifiable or <2 log decline at treatment week 12, respectively [patients with prior virologic breakthrough on PR were not enrolled]). These studies collectively enrolled a diverse group of patients with HCV infection. Patients enrolled in the C-SURFER study had stage 4 or 5 chronic kidney disease with estimated glomerular filtration rate 15À29 mL/min per 1.73 m 2 and <15 mL/min per 1.73 m 2 , respectively. 12 Patients enrolled in C-EDGE CO-INFECTION had HIV co-infection and were either naïve to antiretroviral therapy or were receiving stable antiretroviral therapy with tenofovir or abacavir, and either emtricitabine or lamivudine plus raltegravir, dolutegravir, or rilpivirine. 10 Patients enrolled from C-SALVAGE had previously failed !4 weeks of therapy with PR plus boceprevir, telaprevir, or simeprevir. 13, 22 In all studies, patients with decompensated liver disease (presence or history of ascites, esophageal or gastric variceal bleeding, hepatic encephalopathy, or other signs of advanced liver disease) or evidence of hepatocellular carcinoma were excluded.
To be eligible for inclusion in the present integrated analysis, patients were required to have had Child-Pugh A compensated cirrhosis based on at least 1 of the following criteria: liver biopsy consistent with METAVIR F4 at any time before entry into the study; FibroScan >12.5 kPa within 12 months of study entry; or AST-to-platelet ratio index (APRI) >2.0 and FibroTest >0.75 within 12 months of study entry. Laboratory exclusion criteria differed between the original treatment studies due to the different patient populations enrolled; however, all patients met the inclusion criteria for their initial treatment study, were considered cirrhotic according to biopsy, FibroScan or FibroTest þ APRI criteria, and all had either 6 or 7 Child-Turcotte-Pugh points.
Treatment
All patients received EBR/GZR 50 mg/100 mg once daily with or without RBV (800À1400 mg/d based on body weight), administered either as a co-formulated fixed-dose combination tablet or as separate entities. Treatment-naïve patients were treated for 12 weeks and treatment-experienced patients were treated for 12 or 16/18 weeks.
Outcomes
The primary end point of all 6 studies was SVR12, defined as HCV RNA <15 IU/mL. Plasma HCV RNA levels were measured using the COBAS AmpliPrep/COBAS TaqMan HCV test (version 2.0, Roche Molecular Diagnostics, Branchburg, NJ) with a lower limit of quantitation of 15 IU/mL. In all studies, relapse was defined as detectable HCV RNA after the end of therapy, after undetectable HCV RNA at the end of therapy. Virologic rebound was defined as HCV RNA >1 log increase from nadir while on treatment, and virologic breakthrough was defined as HCV RNA above the lower limit of quantitation after previously being below the lower limit of quantitation. Safety and tolerability were assessed through the monitoring of AEs, vital signs, and laboratory assessments.
Population sequencing was performed at baseline and at the time of virologic failure. The specific NS5A loci evaluated were any polymorphism at amino acid positions 28, 30, 31, and 93 based on data from the EBR/GZR phase 2/3 clinical program, which indicate that only polymorphisms at these 4 positions impact the efficacy of EBR/GZR. 23 HCV RNA was reversetranscribed and amplified using reverse transcription polymerase chain reaction followed by population sequencing of the NS5A gene on an ABI Sequencer from samples with RNA levels of !1000 IU/mL. The limit of minority variant detection in the population was approximately 20% of the viral population.
Analyses
This is an exploratory retrospective analysis of data from phase 2/3 clinical trials. Efficacy analyses are based on the full analysis set population, which includes all randomized patients who received 1 or more doses of drug. The resistance analysis population included all patients with baseline sequencing available and a treatment outcome of either SVR12 or virologic failure.
The safety analysis was based on the all patients as treated population, which includes all patients who received more than 1 dose of study medication. The integrated safety population included an additional 62 treatment-naïve patients with ChildPugh A cirrhosis who were treated for 18 weeks with EBR/GZR with or without RBV in the C-WORTHY studies 14, 15 who were not included in the efficacy analyses. These studies showed that an 18-week treatment regimen with or without RBV provided no incremental benefit in terms of improved efficacy for treatment-naïve patients compared with 12 weeks of therapy. We therefore elected not to include an efficacy analysis of treatment-naïve patients treated for 18 weeks.
Results

Patient Characteristics
A total of 402 patients with Child-Pugh A compensated cirrhosis were included in the present analysis (Table 1) . Most patients were white (n ¼ 324 [81%]) with HCV GT1a (Table 2) . Overall, 42% were treatment-naïve and 58% were treatment-experienced (including 34 patients who had failed treatment on prior PR plus a first-generation protease inhibitor), and 10% of patients (n ¼ 40) had HIV co-infection. Seven patients with stage 4/5 chronic kidney disease from the C-SURFER study were also included. Cirrhosis was diagnosed by biopsy in 29% of patients, by FibroScan in 64% of patients, and by APRI þ FibroTest in 7%. Of the 258 patients diagnosed by FibroScan, 36% had FibroScan values >25.0 kPa. Albumin was <3.5 g/dL in 6% of patients and platelet count was <100,000 cells/mL in 25% of patients.
Four patients discontinued treatment early due to reasons unrelated to study medication: 2 patients died during treatment (1 treatment-naïve patient due to coronary artery disease and 1 treatment-experienced patient due to a motor vehicle accident), and 2 treatment-experienced patients discontinued treatment (1 due to noncompliance and 1 due to lymphoma). No patients were lost-to-follow-up.
Virologic Response
In this integrated population of treatment-naïve cirrhotic patients with HCV GT1 or 4 infection, SVR12 was achieved by 97.8% (135 of 138) of patients receiving EBR/GZR for 12 weeks and 90.3% (28 of 31) of those receiving EBR/ GZRþRBV for 12 weeks (no treatment-naïve patients with HCV GT6 infection were included in this analysis) (Figure 1) . Of the 138 patients not given RBV, 3 failed to achieve SVR12: 1 patient died after completing treatment (coronary artery disease unrelated to study drug) and there were 2 virologic failures (breakthrough, n ¼ 1; relapse, n ¼ 1). The lower response in the EBR/GZRþRBV arm was likely due to the small sample size; evaluable patients came from one treatment arm in the phase 2 C-WORTHY study. Three patients in the RBV-containing treatment arm experienced virologic failure (2 patients with relapse and 1 on-treatment breakthrough).
In treatment-experienced cirrhotic patients receiving EBR/GZR with or without RBV for 12 weeks, or EBR/GZR with or without RBV for 16/18 weeks, SVR rates were 91.4% (74 of 81), 88.9% (48 of 54), 100% (49 of 49), and 93.9% (46 of 49), respectively ( Figure 1 ). In the 12-week arms, 3 treatment-experienced patients discontinued treatment for reasons unrelated to treatment (motor vehicle accident, noncompliance, lymphoma; no RBV, n ¼ 2; RBV, n ¼ 1). Of the 98 treatment-experienced patients included in the 16-/18-week analysis population, 49 received RBV (of which 37 were treated for 16 weeks and 12 for 18 weeks) and 49 did not (of which 38 were treated for 16 weeks and 11 for 18 weeks). All cirrhotic patients receiving EBR/GZRþRBV for 16/18 weeks achieved SVR (49 of 49, 100%, including 37 of 37 treated for 16 weeks) compared with 93.9% (46 of 49) of patients in the no RBV group treated. Complete details of all 18 patients with virologic failure included in this integrated analysis (GT1a infection, n ¼11; GT1b, n ¼ 2; GT1-other, n ¼ 1; GT4/6, n ¼ 3) are provided in Supplementary Table 1 .
Predictors of Response
Subgroup analysis showed high rates of SVR12 across all patient subgroups, regardless of treatment history or baseline demographic characteristics (Table 3) . Of particular note, SVR12 was high regardless of severity of cirrhosis, as indicated by the generally high response rates in patients with albumin <3.5 g/dL, platelets <100 Â 10 3 cells/mL, and FibroScan values >25.0 kPa, although SVR12 tended to be slightly lower among the treatmentexperienced patients in these subgroups who were treated for 12 weeks. There were no patients in this analysis with albumin <3.0 g/dL at baseline. Sixteen treatment-naïve patients and 20 treatment-experienced patients had platelets <75 Â 10 3 cells/mL; SVR was achieved by 15 of the treatment-naïve and 18 of the treatment-experienced patients, respectively. In patients with GT1b infection, SVR was 100% among both treatment-naïve and -experienced patients receiving EBR/GZR without RBV for 12 weeks (56 of 56 in treatmentnaïve patients and 13 of 13 in treatment-experienced patients). In patients with GT4 infection, SVR12 was 100% (6 of 6) in treatment-naïve patients receiving EBR/GZR without RBV for 12 weeks but was lower in treatmentexperienced patients treated for 12 weeks (4 of 6 [67%]) or for 16 of 18 weeks without RBV (1 of 2 [50%]). All 4 treatment-experienced patients with GT4 infection who received EBR/GZRþRBV for 16 of 18 weeks achieved SVR12. Among treatment-naïve patients receiving EBR/GZR for 12 weeks (no RBV), SVR rates were 100% (33 of 33) and 97.1% (102 of 105) in those with baseline viral load 800,000 IU/mL and >800,000 IU/mL, respectively. Among treatment-experienced patients receiving EBR/GZR (no RBV) for 12 weeks, SVR rates were 92.9% (13 of 14) and 87.5% (35 of 40) in those with baseline viral load 800,000 IU/mL and >800,000 IU/mL, respectively. All 36 treatment-experienced patients receiving EBR/GZRþRBV for 16 weeks with baseline viral load >800,000 IU/mL achieved SVR (100%, 36 of 36).
HCV GT1a-infected patients were most likely to have virologic failure. Among patients with GT1a infection receiving EBR/GZR without RBV for 12 weeks, SVR12 was 96.1% (73 of 76; 95% confidence interval [CI], 88.9%À 99.2%) and 88.6% (31 of 35; 95% CI, 73.2%À96.8%) in treatment-naïve and treatment-experienced cirrhotic patients, respectively (Table 3) . A total of 3 treatment-naïve and 4 treatment-experienced patients with GT1a-infection failed to attain SVR: 2 patients discontinued treatment for reasons unrelated to study medication (1 treatmentnaïve patient died after completing treatment and 1 treatment-experienced patient was discontinued due to noncompliance; both had no NS5A RASs at baseline) and the remaining 5 patients relapsed. Among the 35 treatmentexperienced GT1a patients receiving EBR/GZR for 12 weeks, there were 3 virologic failures, all of whom had prior null or partial response to PR. All 3 patients with virologic failure had treatment-emergent NS5A RASs (Supplementary  Table 1 : patients 151237, 680432, and 680801). A full description of the treatment outcomes in patients with HCV GT1a infection, including SVR according to baseline viral load, is presented in Supplementary Table 2 .
Further analysis of patients with GT1a infection receiving EBR/GZR for 12 weeks, based on the presence of baseline NS5A RASs, was conducted in the resistance analysis population, which included patients with available baseline RAS analysis and an outcome of either SVR or virologic failure (Table 4 ). The 2 GT1a-infected patients receiving EBR/GZR for 12 weeks who discontinued treatment for reasons unrelated to study medication were excluded from the resistance analysis population. Among patients with GT1a infection receiving EBR/GZR for 12 weeks, NS5A RASs were detected in 10.7% (8 of 75) of treatment-naïve and 8.8% (3 of 34) of treatmentexperienced patients (Table 4 ). In treatment-naïve GT1a patients receiving EBR/GZR for 12 weeks, SVR12 was achieved by 66 of 67 (98.5%) patients with no NS5A RASs at baseline and 7 of 8 (87.5%) patients with baseline NS5A RASs. Among treatment-experienced GT1a-infected patients receiving EBR/GZR for 12 weeks, SVR12 was achieved by 30 of 31 (96.8%) patients with no NS5A RASs at baseline and 1 of 3 (33.3%) patients with baseline NS5A RASs (34 of 35 treatment-experienced patients with GT1a infection were evaluable for resistance analysis, while 1 patient had 
Safety and Tolerability
Frequently observed AEs, such as fatigue, headache, nausea, and insomnia, were more common in patients receiving RBV compared with those not receiving RBV (Table 5) . Drug-related AEs were also higher among patients receiving RBV (42% vs 73.1%). There was one drug-related serious AE in a 56-year-old cirrhotic white female who reported severe abdominal pain without associated symptoms on day 30 of treatment with EBR/GZR. Physical examination revealed Murphy's sign with no gallstones. Medication was continued and causality for the pain was assessed as possibly related to study medication; the symptoms resolved and did not recur while continuing study medication.
Six patients discontinued treatment due to an AE: 2 were receiving EBR/GZR (lymphoma, ALT elevation, which met protocol-defined stopping rule) and 4 were receiving EBR/ GZRþRBV (uterine bleeding, tachycardia, depression, portal vein thrombosis/colitis). There were 3 deaths (lymphoma, motor vehicle accident, coronary artery disease), all unrelated to study medication. No patient showed signs of liver decompensation during treatment or follow-up, as evidenced by presence of ascites, esophageal or gastric variceal bleeding, hepatic encephalopathy, or severe coagulopathy (international normalized ratio >2.5).
Among patients receiving EBR/GZR without RBV, there were 5 patients with grade 3 (5.1À10.0Â upper limit of normal) and 1 patient with grade 4 (>10Â upper limit of normal) ALT/AST elevations (Table 6 and Supplementary  Table 1) . None of the patients were symptomatic, and the 4 of the 5 patients with grade 3 ALT elevations had peak values occurring at treatment week 6 or later, ranging from 204 to 369 IU/L. One patient had a peak ALT of 211 IU/L at treatment week 1. All 6 patients with ALT/AST elevations achieved SVR12. The patient with a grade 4 ALT and AST elevation was a 52-year-old cirrhotic Asian female on a 12-week treatment course. This patient's eosinophils increased from 0.8% at baseline to 8.8% at treatment week 10, and her international normalized ratio increased from baseline levels of 1.1 to 1.3 at treatment week 10. This was concurrent with a grade 4 ALT/AST elevation (668/459 IU/L) which resulted in the discontinuation of study medication. Her ALT/AST returned to within normal limits (20 IU/L) at follow-up week 4 and she achieved SVR12. This was a protocol-mandated discontinuation based on a protocol-specified stopping rule, and the patient remained otherwise asymptomatic. No patient with elevated ALT/AST had concurrent increased total bilirubin, and no patient had drug-induced liver injury or met criteria for Hy's Law. Regarding other laboratory tests, a decrease in hemoglobin levels was predominantly observed in patients receiving RBV.
Discussion
This integrated analysis presents data from >400 HCVinfected patients with compensated cirrhosis treated with EBR/GZR and diverse patient characteristics, including treatment-naive, interferon-experienced, HIV co-infected, and advanced kidney disease. Consistent with a more advanced Child-Pugh A population, 36% of patients had a Includes all patients who received at least 1 dose of study medication). DC, discontinuation; LTFU, lost-tofollow up.
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FibroScan score >25 kPa, and 25% of patients had a platelet count <100,000 cells/mL at baseline. These data demonstrate that cirrhotic patients with HCV GT1 or 4 infection can achieve high rates of SVR12 with EBR/GZR-based treatment regimens. In treatment-naïve patients, SVR12 was 98% among cirrhotic patients treated for 12 weeks, with no incremental benefit of concomitant RBV therapy, and a 16-week/18-week treatment duration with concomitant RBV in treatment-experienced patients, resulted in a SVR12 of 100%.
High efficacy was maintained across all important patient subgroups, including those with platelet counts 
Values are presented as n (%). APRI, AST-to-platelet ratio index; DAA, direct-acting antiviral; IFN, interferon; P, peginterferon; PR, peginterferon/RBV. a Includes all patients who received at least 1 dose of study medication. There were no patients with albumin levels <3.0 Â 10 3 cells/mL.
<100,000 cells/mL, serum albumin <3.5g/dL, and FibroScan scores >25 kPa, suggesting no decline in efficacy with advanced compensated cirrhosis. The difference in SVR rates between GT1a-infected treatment-naïve and -experienced patients receiving EBR/GZR (no RBV) for 12 weeks (96% vs 89%) may be attributable to the limited number of patients included in this analysis, although an increased impact of RASs in treatment-experienced patients cannot be excluded. Sarrazin and colleagues 24 recently reported that among patients with GT1 infection receiving ledipasvir/sofosbuvir for 12 weeks, SVR12 was 99% and 96% in treatment-naïve patients without and with highimpact baseline NS5A RASs (RASs conferring >100-fold loss of sensitivity to ledipasvir at a frequency of at least 15%), respectively (P ¼ .066); whereas in treatmentexperienced patients, SVR rates in those without and with high-impact NS5A RASs were 97% and 65%, respectively (P < .05).
In the absence of baseline NS5A RASs, a 12-week RBV-free regimen resulted in high rates of SVR12 regardless of treatment history. In total, 11 GT1a-infected patients with baseline NS5A RASs received 12 weeks of EBR/GZR, of which 8 (73%) achieved SVR12, whereas 96 of 98 (98%) of GT1a-infected patients without RASs at baseline achieved SVR12. Although patient numbers are small in this cirrhotic population, increasing treatment duration to 16 of 18 weeks and adding concomitant RBV appeared to overcome the effect of NS5A RASs, a finding similar to that seen in the non cirrhotic population. 19 These data also suggest that if there Two patients (1 treatment-naïve and 1 treatment-experienced) who discontinued treatment early due to administrative reasons were excluded from this analysis (1 patient died after completing treatment, before follow-up week 4, and the other patient was discontinued due to noncompliance; both had no NS5A RASs at baseline). Among patients with relapse, 1 of 2 treatment-naïve patients and 2 of 3 treatment-experienced patients had NS5A RASs present at baseline. c Excludes 1 treatment-experienced patient with unavailable sequence data who also achieved SVR12. NOTE. Values are presented as n (%). Safety population includes 62 additional patients enrolled in C-WORTHY (treatment-naïve cirrhotic patients treated for 18 wk). Discontinuations due to AE: without RBV, lymphoma, and ALT elevation; with RBV, uterine bleeding, tachycardia, depression, and portal vein thrombosis/colitis; placebo, rash. is a history of interferon-based treatment and baseline RAS data are not available, efficacy may be optimized by extending treatment with EBV/GZR to 16 weeks and adding RBV. Data from this analysis are based on population sequencing with a sensitivity threshold of 20% to 25%. Nextgeneration sequencing data are not available for this cohort of cirrhotic patients; however, data from the EBR/GZR clinical program indicate that population sequencing with a sensitivity threshold of 20%À25% and next-generation sequencing with a 10% threshold both identify a comparable small set of EBR RASs among which the efficacy of EBR/ GZR is reduced. Increasing next-generation sequencing sensitivity to a 1% threshold identifies a broader group of EBR RASs, but those have a smaller impact on SVR compared with those identified by population sequencing.
EBR/GZR was generally well tolerated. Six patients discontinued treatment due to an AE, one of which was considered drug-related (abdominal pain). Four patients had late ALT elevations after initially normalizing on treatment and 1 patient discontinued treatment due to a grade 4 ALT elevation with increased eosinophils. There were no decompensation events in this generally healthy cirrhotic population, and no other evidence of declining liver function while on treatment.
Therapeutic treatment options for patients with cirrhosis frequently involve extended treatment durations of 24 weeks and/or the use of RBV. In an integrated analysis of 513 cirrhotic patients receiving sofosbuvir/ledipasvir±RBV, an overall SVR12 rate of 96% was achieved, although SVR12 rates were slightly lower in treatmentexperienced patients treated for 12 weeks (90% vs 98% in patients treated for 24 weeks). SVR rates were also lower in treatment-experienced patients with platelet count <75,000 cells/mL (SVR of 82%) and those with NS5A RASs at baseline (SVR of 85% in cirrhotic patients receiving sofosbuvir/ledipasvir for 24 weeks). 25 The recommended treatment regimen for treatment-experienced patients with compensated cirrhosis is sofosbuvir/ledipasvir for 24 weeks, but a 12-week regimen with addition of RBV is also a therapeutic option for patients who are eligible for RBV therapy. 26 A French randomized, multicenter study has shown similar rates of SVR12 in patients with compensated cirrhosis receiving sofosbuvir/ledipasvirþRBV for 12 weeks compared with those receiving sofosbuvir/ledipasvir alone for 24 weeks (96% vs 97%). 27 In a randomized study of patients with Child-Pugh A cirrhosis receiving paritaprevir/ ritonavir, ombitasvir, dasabuvir, and RBV for 12 or 24 weeks, SVR 12 was achieved by 91.8% and 95.9% of patients in the 12-and 24-week treatment arms, respectively. 28 Cirrhotic patients with HCV GT1a infection require ombitasvir, paritaprevir/ritonavir plus dasabuvir and RBV for 24 weeks. 29 More recently, the combination of sofosbuvir/velpatasvir has received approval as a 12-week regimen for compensated cirrhotic patients with GT1a infection, regardless of treatment history without need for treatment extension or addition of RBV (including for prior direct-acting antiviral failures). 30 Data from the present analysis suggest that SVR12 rates of 98% are achievable with a regimen of EBR/GZR for 12 weeks in the 89%À93% of cirrhotic patients with HCV GT1a infection who have no baseline NS5A RASs. In the small proportion of GT1a-infected patients with NS5A RASs at baseline (6.9%À 10.6% of patients in this analysis), extending therapy to 16 weeks and the addition of concomitant RBV can overcome the negative impact of NS5A RASs.
This integrated analysis is subject to several limitations. The analysis was not prespecified nor powered for statistical comparison between treatment arms. Most patients had well-compensated cirrhosis, and thus these data cannot be extrapolated to patients with more advanced cirrhosis or decompensated disease. Indeed, the use of EBR/GZR is contraindicated in patients with Child-Pugh B or C cirrhosis. Furthermore, subgroup analyses frequently include small numbers of patients, including limited numbers of patients with HCV GT4 or 6 infection. EBR/GZR is not approved for the treatment of patients with HCV GT6 infection, whereas the EBR/GZR prescribing information indicates that patients with GT4 infection should be treated with 12 weeks if treatment-naïve or 16 weeks with the addition of RBV if treatment-experienced. 31 In addition, small numbers of patients are included in several of the patient subgroups with baseline NS5A RASs or previous treatment failure that are used to discriminate extended durations of treatment. However, the conclusions from this analysis of cirrhotic patients are supported by similar observations from larger analyses of noncirrhotic patients receiving EBR/GZR, which also endorse the use of RAS testing to define treatment duration in patients with GT1a infection. 31 Finally, the laboratory criteria used to define cirrhosis differed across the original treatment studies, and the presence of cirrhosis in this analysis population was not based on a single uniform set of diagnostic criteria.
In conclusion, EBR/GZR was highly efficacious in compensated cirrhotic patients. Most patients in our analysis had HCV GT1a or 1b infection. Patients with GT1b infection achieved high rates of SVR12 with all regimens evaluated, including EBR/GZR for 12 weeks, regardless of the presence or absence of RASs; whereas the presence of NS5A RASs can be used to define the optimum treatment regimen in patients with GT1a infection. If RAS testing is unavailable, an alternative approach is to use history of prior treatment failure to define an optimal regimen. Only 1 patient discontinued treatment due to a protocol-mandated stopping rule and no patient experienced a decompensation-related event. These data suggest that EBR/GZR for 12 weeks is a safe and effective treatment option for the majority of compensated cirrhotic patients with HCV GT1 infection. An intensified regimen with RBV for 16 weeks is required for GT1a-infected patients with baseline NS5A RASs.
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